title: TAT modified and lipid - PEI hybrid nanoparticles for co-delivery of docetaxel and pDNA.
abstract: BACKGROUND
  Co-delivery of anticancer drugs and gene is promising to generate synergistic anticancer effects. Surface modification of nanocarriers with specific ligands could further assist in targeting and internalization of the nanocarriers into specific cell populations, such as cancers and disease organs.
  
  
  OBJECTIVE
  The aim of the study reported here is to develop Cell-penetrating peptides (CPPs) modified lipid - PEI hybrid nanoparticles (LPNs) for effective co-delivery of docetaxel (DTX) and plasmid DNA (pDNA) for combination chemotherapy.
  
  
  METHODS
  RKKRRQRRR peptide (TAT) modified, DTX and pDNA loaded LPNs (TAT-DTX/pDNA LPNs) were prepared and evaluated in PC3 cancer cells (in vitro) and in a murine prostate cancer model (in vivo).
  
  
  RESULTS
  The results illustrated that the in vitro anticancer effect, in vitro transfection efficiency, in vivo antitumor and gene delivery efficacy of TAT-DTX/pDNA LPNs have advantages over other formulation tested.
  
  
  CONCLUSIONS
  The results demonstrated that TAT-DTX/pDNA LPNs could be a promising co-delivery nano-system to achieve therapeutic efficacy for treatment of cancer.
authors.affiliation: Department of Pharmacy, Linyi People's Hospital, Linyi, Shandong, PR China.
authors.forename: Shufang
authors.initials: S
authors.lastname: Dong
authors.affiliation: Department of Pharmacy, Linyi Cancer Hospital, Linyi, Shandong, PR China.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Department of Pharmacy, Linyi People's Hospital, Linyi, Shandong, PR China. Electronic address: yjysdpro@163.com.
authors.forename: Jiying
authors.initials: J
authors.lastname: Yang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D004247:DNA / Q000008:administration & dosage*; D000077143:Docetaxel; D016503:Drug Delivery Systems; D065546:Drug Liberation; D005260:Female; D018014:Gene Transfer Techniques; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D010446:Peptide Fragments / Q000378:metabolism*; D010957:Plasmids / Q000008:administration & dosage; D011094:Polyethyleneimine / Q000737:chemistry*; D055672:Static Electricity; D043823:Taxoids / Q000494:pharmacology*; D014162:Transfection; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D008055:Lipids; D010446:Peptide Fragments; D043823:Taxoids; D054322:tat Gene Products, Human Immunodeficiency Virus; C490722:tat peptide (49-57), Human immunodeficiency virus 1; D000077143:Docetaxel; D011094:Polyethyleneimine; D004247:DNA
keywords: Cell-penetrating peptides; Co-delivery; Docetaxel; Gene; Lipid – hybrid nanoparticles